On GLP-1 treatment (Mounjaro, Ozempic, Wegovy), eating well is essential. Discover menus inspired by French, Spanish, Italian and Brazilian cuisines: high in protein, easy to digest and adapted to every stage of your treatment.
GIP receptors are the key differentiating factor for Mounjaro. Their role in adipose tissue, the brain, and bones explains the superiority of tirzepatide.
Tirzepatide Half-Life: How 3 Chemical Modifications Transform a 3-Minute Hormone into a Weekly Treatment. Pharmacokinetics Explained.
How tirzepatide reduces appetite: mechanisms of satiety, food noise, neuronal signals. What patients experience and how to optimize.
Zepbound and Mounjaro contain the same tirzepatide. What are the differences? Indications, reimbursement, availability in France. All you need to know in 2026.
Mounjaro vs Wegovy: complete 2026 comparison. Weight loss, side effects, cardiovascular benefits, cost. Which one to choose based on your profile?
You might feel overwhelmed by the complexity of obesity treatments available today. We will review your therapeutic options together, clearly and without judgment.
Mounjaro vs Ozempic: A comprehensive comparison of the two GLP-1 treatments. Efficacy, side effects, price, and selection criteria based on clinical studies.
Have you just started Mounjaro or has your doctor prescribed it to you? It’s completely normal to have questions about possible side effects. Rest assured, most Mounjaro side effects are predictable, temporary, and there are concrete ways to minimize them.
A France TV investigation has set the record straight on obesity, debunking the stubborn misconception that it’s merely a lack of willpower. The documentary highlights concrete biological and social factors that explain why we are not all equal in the face of this disease.
GLP-1 and GIP: discover the role of these two incretin hormones targeted by tirzepatide (Mounjaro). Mechanisms of action, differences, and synergy for weight loss.
Mounjaro, with its active ingredient tirzepatide, marks a significant advancement in treating type 2 diabetes and obesity. This revolutionary drug, developed by Eli Lilly, received FDA approval in May 2022 and EMA approval in September 2022.